Author Manuscript
Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

UNIL | Université de Lausanne

Faculté de biologie
et de médecine

Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

3

4

Sam Vasilevsky[1,2], Gilbert Greub[2], Denise Nardelli-Haefliger[3] and David Baud[1,2 #]

6

[1] Materno-fetal & Obstetrics Research Unit, Department of Obstetrics and Gynecology, University hospital, 1011 Lausanne, Switzerland

[2] Center for Research on Intracellular Bacteria, Institute of Microbiology, Faculty of Biology and Medicine, University of Lausanne, 1011 Lausanne, Switzerland

[3] Dpt. of Urology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011 Lausanne, Switzerland

13

Running Head: Immunity and *Chlamydia* Vaccine

Keywords: *Chlamydia*, vaccines, immunology, macrophages, dendritic cells, T cells

16

#Corresponding author: David Baud, MD PhD

Department of Obstetrics and Gynecology

University hospital

Centre Hospitalier Universitaire Vaudois (CHUV)

1011 Lausanne

SWITZERLAND

Phone: (00) 41 79 556 13 51

Email: david.baud@chuv.ch

47

48

49

50

51

52

53

54 **SUMMARY**

55   Despite significant advances in the understanding of the host response to chlamydial

56 infection and over 30 years of vaccine research, *Chlamydia trachomatis* remains the leading

57 cause of bacterial sexually transmitted disease worldwide. This gram-negative obligate

58 intracellular bacterium, that often remains asymptomatic, may cause pelvic inflammatory

59 disease (PID), ectopic pregnancies, scarring of the fallopian tubes, miscarriage and infertility

60 when left untreated. In the genital tract, *Chlamydia trachomatis* primarily infects epithelium

61 cells and requires Th1 immunity for optimal clearance. This review first focuses on the

62 immune cells important in a chlamydial infection. Secondly, we will summarize the research

63 and challenges associated with developing a chlamydial vaccine that elicits a protective Th1-

64 mediated immune response without inducing adverse immunopathologies.

65

66 **INTRODUCTION**

67   *Chlamydia trachomatis* is the leading cause of bacterial sexually transmitted diseases

68 in humans. According to the WHO in 2008, there was 105 million new cases of STDs each

69 year due to *C. trachomatis* worldwide and the infection rate has been steadily increasing (9,

70 103). When symptomatic, *C. trachomatis* can lead to mucopurulent endocervical discharge,

71 hypertrophic cervix, and post coital bleeding. In 20-40% of untreated women *C. trachomatis*

72 may reach the fallopian tubes via the endometrial epithelium and cause pelvic inflammatory

73 disease (PID). However, *C. trachomatis* genital tract infections are often asymptomatic (75-

74 90%) and therefore remain undiagnosed and untreated. This can lead to tubal factor infertility

75 or ectopic pregnancies (68, 69), which is a life threatening condition. *C. trachomatis* can be

76 easily treated with antibiotics such as erythromycin, azithromycin or doxycycline. However,

77   several studies have documented that within a year after treatment for a *C. trachomatis*

78   infection, 13-26% of individuals showed evidence of persistent or recurrent infections (38,

79   51). Therefore, due to the high rate of asymptomatic infections, recurrent infections and the

80   severity of pathologies induced by *Chlamydia,* the development of a vaccine is paramount.

81   This review focuses on *C. trachomatis* and *C. muridarum* (a model organism that naturally

82   infects rodents and largely used for animal experiments) immunity and the challenges

83   associated with generating a vaccine against this bacterium. Table 1 summarizes recent

84   developments in chlamydial research including *Chlamydia* strain or antigen used, cell type

85   affected and immune response elicited.

86

87   *CHLAMYDIA* **BIOLOGY**

88   The genus *Chlamydia* includes species that infect humans (*C. trachomatis*, *C.*

89   *pneumoniae*), and animals (*C. muridarum, C. suis*, *C. abortus*) (21). Presently, there have

90   been 18 identified serovars of *C. trachomatis* based on the reactivity of patient sera to the

91   major outer membrane protein (MOMP) (135). Some serovars are associated with ocular

92   tissue infections (A-C) while others primarily infect genital tissues (D-K) (7). *C. trachomatis*

93   is a gram-negative obligate intracellular bacterium that in the genital tissues normally infects

94   the epithelium layer of the cervix of women and the urethra of men (12).

95   *Chlamydia* exists in two developmental forms, the infectious extracellular non-

96   replicating elementary body (EB) and the non-infectious intracellular replicating reticulate

97   body (RB). The EB displays no metabolic activity, is resistant to both chemical and physical

98   factors, and is adapted for prolonged extracellular survival. Infection begins when the small

99   (~0.2-0.3μm) EB attaches to the host cell and is internalized inside an entry vacuole which

100 avoids fusion with the lysosome. After 8-10 hours the vesicle bound EB (termed an inclusion)

4

101 replicates by binary fission into the larger (~0.8 µm) RB (138). Following several rounds of

102 division, the RB`s reorganize and revert back to the EB (131). Inside host cells, *C.*

103 *trachomatis* circumvents endogenous stress mechanisms, prevents lysosomal fusion and

104 escapes intracellular destruction by replicating in an inclusion outside of the endocytic

105 pathway (138). *C. trachomatis*-infected cells have increased inducible oxide synthase (iNOS)

106 and increased pro-inflammatory molecules such as activins, which may be involved in

107 scarring (1, 115).

108

109 **IMMUNITY TO *CHLAMYDIA***

110 **T cells**

111   A critical role for T cells in immunity to *Chlamydia* was demonstrated almost 30 years

112 ago when Rank *et al*. observed that athymic nude mice established chronic infection with *C.*

113 *muridarum* after intravaginal inoculation whereas wild-type (wt) mice resolved the infection

114 in 20 days (114). In human and mouse models, both CD4+ and CD8+ T cells can be detected

115 at the site of *C. trachomatis* infection (65, 71, 101, 129). T cells are unable to recognize

116 pathogens or antigens without the help of antigen presenting cells (APC) such as dendritic

117 cells (DC), macrophages, or B cells. APC are able to phagocytose chlamydial EBs in the

118 extracellular space or engulf infected cells harboring RBs. After phagocytosis, APC degrade

119 chlamydial components and present the peptides via MHC class II-antigen complex to CD4 +

120 T cells or MHC class I-antigen complex to CD8 + T cells. In fact, numerous *C. trachomatis*

121 antigens have been identified which can be recognized by human CD4+ and CD8+ T cells

122 including the cysteine-rich outer membrane protein 2 (Omp2) (40), polymorphic outer

123 membrane protein D (POMP-D) (41), MOMP (50, 72, 104), heat shock protein 60 (hsp 60)

124   (25, 50), chlamydial protease activating factor (CPAF) (75), PmpG, PmpF, and RpIF (66,

125   101). High-throughput proteomic screening has identified even more potential

126   immunodominant *C. trachomatis* antigens including 36 that have been shown to react with

127   sera from three strains of mice immunized with live *Chlamydia* and two protein antigens that

128   were able to induce a polyfunctional Th1 CD4+ T cell response and high Th1 antibody titers

129   (112, 126). Although *Chlamydia* is able to induce a Th2 response characterized by IL-4 and

130   Th2-associated antibodies such as IgG1, a Th1 response predominates characterized by the

131   production of IL-12 by APC (17) and the subsequent activation of IFN-γ producing T cells

132   and plasma B cells that secrete Th1-associated antibodies such as IgG2a and IgG3 (97, 100).

133   However, a recent study demonstrated that CD4+ T cells from women with genital tract *C.*

134   *trachomatis* infection that were restimulated *ex vivo* with inactivated (γ-irradiated) EB secrete

135   significantly more IL-4 than TNF-α and IFN-γ. This study suggests that the type of immune

136   response (Th1 vs Th2) to *C. trachomatis* may be tissue specific (132).

137   While there is ample evidence that CD4+ T cells play an integral part in the resolution

138   of *C. trachomatis* and *C. muridarum* infections (34, 36, 39, 60), the role for CD8 + T cell has

139   been controversial even though CD8+ T cells are induced following infection and *Chlamydia*-

140   specific human and mouse CD8+ T cells are cytotoxic for *Chlamydia*-infected target cells

141   (137). A recent study by Murthy *et al*. demonstrated that wt and CD8+ T cell-deficient mice

142   displayed similar clearance of *C. muridarum* following vaginal chlamydial challenge (92).

143   These data support previous studies which demonstrated that CD8+ T cells are not critical for

144   *C. trachomatis* clearance (87, 88, 121). Furthermore, the CD8+ T cell-deficient mice

145   demonstrated reduced oviduct pathology (hydrosalpinx) compared to wt, suggesting a role of

146   CD8+ T cells in chlamydial pathogenesis (92). An interesting study demonstrated that the

147   majority of CD8+ T cells in the cervix before and after a *C. trachomatis* infection do not

148   express perforin (53). Perforin is a cytolytic protein found in the granules of CD8+ T cells

149   which forms a pore by inserting itself into the cells plasma membrane resulting in lysis of the

150   target cell. Therefore, the lack of perforin in endocervix CD8+ T cells may explain why

151   CD8+ T cells do not play a critical role in the elimination of genital chlamydial infection.

152   Although CD8+ T cells appear not to be critical in resolving a chlamydial infection and may

153   even contribute to chlamydial sequelae, they nonetheless may play a contributory albeit

154   secondary role by regulating other cells and by their own production of IFN-γ (137).

155   **Dendritic Cells**

156   Dendritic cells (DC) are known to be the quintessential antigen presenting cells.

157   Immature DC are highly phagocytic and after internalization of pathogens they degrade the

158   components and present the peptides to T cells via MHC receptors activating the T cells and

159   initiating a cell- mediated and / or humoral immune response. The capacity of DCs to present

160   chlamydial antigens to T cells, secrete Th1 cytokines such as IL-12 and TNF-α and the

161   importance of MHC class molecules in chlamydial infection has been demonstrated both *in*

162   *vitro* and *in vivo* (64, 84, 87, 99, 122). An early study conducted by Lu and Zhong showed

163   that bone marrow derived dendritic cells (BMDC) pulsed with heat-killed *C. trachomatis* and

164   adoptively transferred into a naive mouse was protective against a subsequent challenge with

165   live *C. trachomatis* in a mouse lung infection model (82). This protection was mediated by a

166   Th1 response further demonstrating a correlation between Th1 skewed immunity and

167   protection against chlamydial infection. In contrast, DCs that were pulsed with recombinant

168   MOMP and adoptively transferred into mice elicited primarily the Th2-associated antibody

169   IgG1 (119). Furthermore, IL-10 (Th2-associated cytokine) KO DC pulsed with UV-

170   inactivated *C. trachomatis* and adoptively transferred activated a high frequency of Th1 cells

171   (47). These data have direct relevance to vaccine development because it indicates that the

172   type of cytokines produced and antigens processed by the DC and presented to CD4+ T cells

173   is essential in the Th1/Th2 balance of the immune response to *Chlamydia*. There is also

174   evidence that live *Chlamydia* is required for an optimal and protective immune response. Rey-

175   Ladino and colleagues demonstrated that the level of protection induced by DC pulsed with

176   UV-inactivated *C. trachomatis* EB and adoptively transferred into mice was significantly less

177   than in mice that were challenged with live EB pulsed DC (116). A more recent study

178   discovered that murine DCs pulsed with live *C. muridarum* EBs presented 45 MHC class II

179   peptides mapping 13 proteins whereas dead EBs presented only six MHC class II peptides

180   mapping to three proteins (143). However, *C. trachomatis* has developed strategies to limit

181   the presentation of these antigens to T cells by downregulating MHC expression on APC (54).

182   *C. trachomatis* has been shown to inhibit MHC molecules within infected cells through the

183   degradation of the MHC class I transcription factor RFX-5 and the MHC class II transcription

184   factor USF-1 by secreting the chlamydial protease CPAF into the cytosol (29, 111, 145, 146).

185   DC are important to vaccine research because they are the critical links between innate and

186   adaptive immunity. Two recent studies using DC transfected with a recombinant adenovirus

187   carrying *C. trachomatis* MOMP antigen (81) and DC pulsed *ex vivo* with recombinant *C.*

188   *trachomatis* protease-like factor (rCPAF) (75) illustrate the ability of DC to induce protective

189   immunity against genital *C. trachomatis* and *C.muridarum* challenge respectively.

190   **Macrophages**

191   Studies using both *C. trachomatis* and *C. muridarum* have shown that macrophages

192   are recruited to sites of infection (88) and are capable of phagocytosing *Chlamydia* (8).

193   Macrophages are also a source of both proinflammatory cytokines such as IL-8, IL-6 and

194   TNF-α (6, 141). However, unlike epithelial cells, macrophages are not a hospitable niche for

195   chlamydial intracellular replication illustrated by the fact that compared to epithelial cells

196   only a small fraction of chlamydial RBs are detected in macrophages (124). *C. trachomatis*

197   destruction inside the macrophage has been associated with host cell autophagy, a process by

198   which cells degrade cytoplasmic proteins and organelles (2, 124, 140), and studies have

199   demonstrated that macrophage autophagy can enhance antigen presentation to T cells (22).

200   Furthermore, INF-γ has been shown to enhance both autophagy and upregulation of MHC

201   class molecules in macrophages (2, 15). This is relevant because, in addition to activating

202   primed T cells, there is evidence suggesting that macrophages are able to initiate a humoral

203   response in naive mice (130). Therefore, enhanced upregulation of MHC molecules

204   containing chlamydial antigens may induce T cells to initiate both a cell-mediated and

205   antibody immune response against *Chlamydia*. However, Jendro *et al*. demonstrated that

206   human macrophages infected with *C. trachomatis* can induce T cell apoptosis (61, 62). In

207   addition to efficiently eliminating *Chlamydia* and presenting the peptides to T cells,

208   macrophages may also have an effect on chlamydial infection by inducing T cell death and

209   perpetuating a persistent infection.

210   **B cells/Antibodies**

211   Previous studies demonstrated that anti-*Chlamydia* antibodies correlated with

212   protective immunity against *C. trachomatis* in humans (4, 59) and numerous *C. trachomatis*

213   proteins have been shown to induce antigen specific antibodies (36). However, even though

214   anti-*Chlamydia* antibodies are able to neutralize infection *in vitro* (5, 13) growing evidence

215   show that B cells may not play a critical role in controlling a primary chlamydial infection but

216   are important for a secondary memory response (89, 90). Several mechanisms have been

217   proposed on how B cells contribute to immunity during re-infection. These mechanisms

218   include antibody-mediated neutralization and opsonization (5), antibody-dependent cellular

219   cytotoxicity (ADCC) (86) (a mechanism of cell-mediated immune defense whereby cells that

220   have antibodies attached to their surface are targeted for lysis), and the formation of antigen-

221 antibody complexes that bind Fc receptors on the APC which then enhances phagocytosis and

222 antigen presentation to the CD4+ T cell (57).

223 Heat shock proteins (hsp), which are found in both eukaryotic and prokaryotic

224 organisms, are stress-proteins that are involved in the correct folding of intracellular proteins.

225 *C. trachomatis* is known to secrete hsp`s during an infection and antigenic epitopes from the

226 bacterial hsp`s have proven to be strong inducers of cellular and humoral immunity.

227 Chlamydial hps60 exhibits over 70% sequence homology and 100% amino acid homology of

228 four defined epitopes with human hsp60 (3) and several studies have suggested that

229 autoimmunity to human hsp60 is a result of cross reactivity after a chlamydial infection (27,

230 136). However, a recent study demonstrated an association with tubal factor infertility (TFI)

231 and antibodies to MOMP and hsp60 from *C. trachomatis* but no connection between TFI and

232 antibodies to human hsp60 (49) pointing to an infectious rather than an autoimmune response

233 as the cause of TFI.

234 In conclusion cell-mediated immunity that activates macrophages, neutrophils and

235 mediators such as IL-12, IFN-γ and TNF-α is required for initial clearance. However, for

236 protective immunity both cell-mediated and humoral immunity are needed including antigen-

237 specific T cells and antibodies that enhance uptake, processing and presentation of chlamydial

238 antigens by DC for a rapid Th1-mediated chlamydial clearance.

239

240 **VACCINES**

241 Due to increasing rates of mainly asymptomatic *C. trachomatis* infections worldwide

242 and the adverse long term consequences resulting from these infections (ectopic pregnancy,

243 infertility, preterm birth) developing an anti-chlamydial vaccine is paramount. However, a

244 human vaccine that elicits both T cell and B cell immunity has been elusive. Although the two

murine models using *C. trachomatis* and *C. muridarum* are the most common models used for chlamydial vaccine research non-human primates, pigs and guinea pigs have also been utilized (24). Our poor understanding of the immune response in the female genital tract, which is highly regulated by sex hormones during the menstrual cycle (52), the lack of adjuvants that not only optimize the immune response to *Chlamydia* antigens but can target the vaccine-specific-immune responses to the site of infection and limited understanding of what type of chlamydial antigens induce a protective immune response hinder the development of a human *C. trachomatis* vaccine. *C. trachomatis* vaccine has to induce both mucosal and systemic immune responses, but autoimmune cross reactions with human antigens and unregulated inflammation that causes pathology has to be avoided. Table 2 summarizes recent chlamydial antigens, delivery systems, routes of vaccination and infection and the subsequent immune responses elicited.

Intact attenuated organisms

Successful vaccines against ovine enzootic abortions have been available for many years (32). These vaccines consisted of live attenuated or inactivated *C. abortis* strains and provided proof of principle that a successful vaccine against *Chlamydia* was possible in mammals. However, these vaccines did not prevent infectivity and lacked the rigorous immunization schedules, efficacy, safety and toxicity standards required for human vaccine (56, 85). Nonetheless, because of the success of these vaccines, live attenuated *C. trachomatis* bacteria were used as the first human *Chlamydia* vaccines (43). Attenuation was induced by either mutagenesis or by growing the organisms in culture. In the latter approach, after several passages, one or more mutations arise, which may result in a nonvirulent attenuated strain. Vaccines with live organisms are generally considered optimal because they contain virtually all of their antigenic determinants in the correct three dimensional conformation. Moreover,

11

269 they replicate similarly to the target pathogen thus promoting the processing and presentation

270 of antigens similar to natural infection and eliciting humoral and cell-mediated immunity.

271 However, using live attenuated organisms for vaccines has drawbacks because large scale

272 production of pure *Chlamydia* is extremely complex and these vaccines need cold storage.

273 Even more importantly, they can also revert to virulent wild-type strains resulting in disease

274 or persistent infection (26).

275   Initial vaccine human trials using live attenuated *C. trachomatis* led to partial short-

276 lived protection, however some individuals who were re-exposed to *Chlamydia* developed a

277 more severe pathological delayed-type hypersensitivity (DTH) response than those that did

278 not receive the vaccine (43). Because of the safety issues of live vaccines, research switched

279 to organisms that were heat or chemically-inactivated. The major disadvantage of these types

280 of vaccines is the absence of replication and poor induction of cell-mediated immunity, which

281 is critical for the clearance of *Chlamydia*, necessitating the need for re-vaccination and

282 adjuvants. Heat or chemical bacterial inactivation may also release unwanted and detrimental

283 components which can have deleterious effects or degrade protein antigenic determinants

284 thereby reducing the degree of protection. Recently, plasmid-deficient *Chlamydia* strains

285 have been used in vaccine research with conflicting results. O`Connell *et al*. demonstrated

286 that a plasmid-deficient strain of *C. muridarum* (Nigg) that is defective in its ability to

287 accumulate glycogen did not cause inflammatory pathology in mice. Furthermore, the

288 plasmid-deficient bacterium protected mice against a secondary infection with plasmid-

289 competent virulent *C. muridarum* (97). However, a different group demonstrated that mice

290 vaccinated with an attenuated plasmidless *C. trachomatis* (L2R) were not protected from

291 colonization and inflammatory pathology after a secondary challenge with wild-type *C.*

292 *trachomatis* (serovar D) although there was a reduction in infectious burden at early time

293 points (100).

Subunit antigenic determinants

Another vaccine strategy utilized is the administration of purified antigenic determinants known to elicit an immune response. Subunit vaccines are safer than attenuated or heat/chemically inactivated organisms because they cannot revert to a virulent form and undesirable antigens that might induce immunopathology can be avoided. One of the most studied vaccine candidate for *C. trachomatis* is the structurally and immunologically dominant protein in the chlamydial outer membrane MOMP. This membrane protein contains several conserved CD4+, CD8+, and B cell epitopes (96) . An early study conducted by Pal and colleagues demonstrated that *C. muridarum* COMP (chlamydial outer membrane complex), a chlamydial outer membrane with a cysteine cross-linked protein shell, significantly protected mice against genital challenge whereas MOMP did not (108). Several years later the same group administered purified and refolded preparation of *C. muridarum* MOMP along with Freund`s adjuvant. The refolded MOMP-Freunds adjuvant conferred a significant level of protection in the vaccinated mice against a genital infection demonstrating the importance of adjuvants and a correct MOMP configuration in eliciting a protective immune response (109). Tiffrea *et al.* discovered that a polymer that keeps membrane proteins soluble (amphipol) in aqueous solution was able to stabilize MOMP and enhance its protective ability as a vaccine (128). Another group immunized mice with a *C. trachomatis* MOMP-ISCOM vaccine. ISCOM (immune stimulating complex) which are mainly composed of cholesterol, phospholipids and saponin, are known to induce both a cell-mediated and humoral response when used as vaccine adjuvants. Inoculation with MOMP-ISCOM was able elicit a Th1 antigen-specific response and vaginal infection was cleared within one week (58). A *C. muridarium* MOMP native preparation combined with an adjuvant consisting of nontoxic subunit B cholera toxin conjugated to CpG (CTB-CpG) elicited a significant cell

318 mediated and antigen-specific antibody response against a pulmonary challenge with *C.*

319 *muridarum* (18). A non-human primate model was used to demonstrate the efficacy of a

320 vaccine formulated with native MOMP. Rhesus macaques that were immunized

321 intramuscularly and subcutaneously along with the adjuvants CpG-2395 and Montanide ISA

322 720 produced high levels of Th1 cytokines (INF-γ, TNF-α) and *C. trachomatis*-specific IgG

323 and IgA (19). Drawbacks of subunits vaccines include the fact that extracting, refolding and

324 purifying protein complexes such as MOMP is very expensive and purifications are not

325 standardized so difference in extraction methods may influence the conformation of the

326 protein epitopes and vaccine efficacy.

327 **Recombinant proteins**

328   The advent of recombinant DNA technology has made it possible to produce large

329 quantities of bacterial proteins. Thus, different attempts were made to use rMOMP in *C.*

330 *trachomatis* vaccine. Unfortunately, producing rMOMP with its native conformational

331 epitopes intact on a large scale is challenging and in some expression systems full-length

332 rMOMP is toxic (78, 147). In 2009, a comparison of vaccines using native or recombinant

333 MOMP demonstrated that the degree of protection obtained with recombinant MOMP was

334 not as robust as that achieved with native MOMP preparation (123). However, other studies

335 using rMOMP with and without adjuvants demonstrated protection against *Chlamydia* (98,

336 127). In 2011, Kalbina and colleagues designed a chimeric gene construct containing two

337 antigenic regions of MOMP and introduced the construct into a bacteria (*Escherichia coli*)

338 and two plants (*Arabidopsis thaliana*, *Daucus carota*). The construct was successfully

339 expressed *in E. coli*, and stable integration of the transgene was demonstrated in *A. thaliana*

340 and *D. carota* over several generations. The rMOMP purified from *E. coli* was used to

341 produce antibodies in rabbits and these antibodies recognized the proteins in both *E. coli*, *A.*

14

342 *thaliana*, *D. carota* as well as in inactivated *C. trachomatis* elementary bodies. The stability

343 of the construct in the offspring plants suggests that this system may be useful for large scale

344 production of rMOMP and the authors plan to use the transgenic plants as edible vaccine

345 vectors for laboratory animal experiments (67).

346 Other recombinant proteins besides MOMP have also been shown to be potential

347 vaccine candidates. In 2007, Murphy *et al.* investigated the potential of recombinant CPAF to

348 elicit an immune response that would resolve chlamydial infection. Mice immunized

349 intranasally with rCPAF and IL-12 (Th1 cytokine) demonstrated increased IFN-γ, and

350 minimal IL-4 (Th2 cytokine) production, elevated IgG2a (Th1) and IgA (mucosal) antibody

351 levels, displayed a markedly reduced bacterial burden upon *C. muridarum* genital inoculation

352 and were protected against pathological consequences of *Chlamydia* infection compared with

353 mock immunized mice (91). The same group demonstrated that rCPAF intranasal vaccination

354 may prevent infertility from repeated genital *C. muridarum* infections in mice (93). Mice

355 immunized with a recombinant chlamydial glycogen phosphorylase (GlgP) and intravaginally

356 challenged with live *C. muridarum* elicited a Th1-dominant T cell response that included anti-

357 chlamydial antibodies and reduced hydrosalpinx severity. Additionally, the GlgP-immunized

358 mice exhibited a significant reduction of vaginal shedding on day 14 post-infection (76).

359 Olsen *et al.* utilized two recombinant proteins in a subunit chlamydial vaccine. The fusion

360 protein CTH1 consisted of CT443 (omcB) which is known to elicit both a humoral and cell-

361 mediated response and CT521 (rl 16) a known target for cells during natural infection in

362 humans. Immunization with CTH1 along with the strong Th1 inducing adjuvant CAF01

363 elicited TNF-α, IL-2 and INF-γ production from T cells and high titers of both Th1 (IgG2a)

364 and Th2 (IgG1) CTH1-specific antibodies. The vaccine significantly reduced bacterial

365 shedding after a vaginal challenge with live *C. trachomatis* and *C. muridarum* and protection

366 was demonstrated to be solely CD4+ T cell-mediated in the *C. muridarum* model (102). Lu

15

367 and colleagues screened 5 recombinant chlamydial antigens (ABC transporter [ArtJ], outer

368 membrane complex protein B [OmcB], macrophage infectivity potentiator [Mip], inclusion

369 membrane protein [Inc (crpA:TC0726)], and an hypothetical protein), that were previously

370 found to react with sera from intravaginally *C. muridarum* infected mice for their ability to

371 induce protection against chlamydial infection. Only Mip induced pronounced protection

372 which was characterized by Th1-dominant T cell response and anti-Mip antibodies (80).

373 **Plasmid DNA**

374 DNA vaccines work by injecting a plasmid that encodes a specific gene of interest

375 within the host. The product of the gene can then be expressed inducing an immune response.

376 DNA vaccines have several advantages compared with other vaccination strategies. DNA can

377 be easily and inexpensively purified and plasmid vectors can be rapidly constructed and easily

378 tested (79). Additionally, DNA vaccines can encode for multiple epitopes that are in the

379 native three dimensional configuration and avoid the problem associated with attenuated

380 organisms which are able to revert back to virulent forms. However, as with other vaccine

381 strategies, DNA vaccines have some disadvantages. In autoimmune diseases such as lupus

382 anti-DNA antibodies are produced and there is the possibility that bacterial DNA injection

383 could elicit a humoral response that cross-reacts with the host DNA. Also, because DNA

384 encodes for proteins, DNA vaccines cannot be utilized for non-protein based antigens such as

385 polysaccharides or lipids (73) and although likely rare, there is the risk that DNA could

386 integrate into the host chromosome (35). In 1999 Pal and colleagues immunized mice with a

387 DNA vaccine that encoded for the MOMP gene of *C. trachomatis*. When the mice were

388 vaginally challenged with *C. trachomatis* the immune response was modest and the mice were

389 not protected against infection (106). The following year Dong-Ji *et al*. demonstrated that

390 immunization with DNA-MOMP and boosting with MOMP-ISCOM conferred higher

16

391 protection against *C. trachomatis* when compared with mice that were only immunized with

392 MOMP-ISCOM (28). More recently two studies using a pig model assessed the efficacy of

393 DNA chlamydial vaccines. Schautteet *et al.* combined aerosol-vaginal delivery of DNA

394 vaccine encoding for MOMP co-administered with DNA encoding for three different

395 adjuvants (GM-CSF, *E. coli* enterotoxin subunit A and B). Vaccination induced significant

396 protection against genital *C. trachomatis* challenge although the infection was not completely

397 resolved (117). Ou and colleagues demonstrated that an OmpA-based DNA vaccine against

398 *Chlamydia abortus* in piglets elicited higher antigen-specific IgG antibodies and T cell

399 proliferative response compared with controls (105). Mammalian cells transfected with a

400 plasmid encoding for MOMP epitopes inserted in a human papillomavirus (HPV) major

401 capsid protein L1 was used in a murine model of *C. trachomatis* genital infection.

402 Intramuscular administration elicited a Th1 response characterized by low IL-4 production

403 and antibodies against MOMP (139). All of these recent studies demonstrate the feasibility of

404 DNA-based vaccine and this approach thus deserves further study.

405

406 **OTHER CHLAMYDIAL VACCINES AND DELIVERY SYSTEMS**

407 **Bacterial ghosts**

408 Bacterial ghosts (BGs) are cell envelopes derived from Gram-negative bacteria. BGs

409 are devoid of all cytoplasmic content but have a preserved cellular morphology including all

410 cell surface structures. BGs are non living but retain all of the antigenic components of their

411 living counterparts and the inside of the BG envelope can be loaded with peptides, drugs, or

412 DNA (74). In 2007, a vaccine system in which a DNA plasmid that encoded for *C.*

413 *trachomatis* MOMP and the porin protein (PorB) was inserted into a recombinant *Vibrio*

414   *cholerae* ghost (rVCG) was used.   Animals that were immunized intramuscularly with the

415   DNA-bacterial ghost vaccine completely resolved a *C. trachomatis* genital infection after two

416   weeks post-infection. The inflammatory response was Th1, characterized by high levels of

417   IgA and IgG2a (55). More recently, Eko and colleagues used the rVCG that contained PorB

418   and chlamydial polymorphic membrane protein-D (PmpD) proteins to evaluate its ability to

419   induce chlamydial immunity. Intramuscular immunization elicited high levels of Th1-

420   associated antibody IgG2a, mucosal-associated antibody IgA, IFN-γ (Th1) and low levels of

421   IL-5 (Th2) in response to an intravaginal *C. muridarum* infection (31).

422   **Biodegradable polymers**

423   PLGA (poly D, L-lactide-co-glycolide) is an FDA approved polysaccharide that can

424   encapsulate peptide, proteins or DNA. PLGA`s are efficiently phagocytosed by DC and

425   macrophages (83, 134) and PLGA antigens are able to be presented on both MHC class I and

426   II molecules thus activating CD4+ and CD8+ T cells (45, 133). Chitosan is a linear

427   polysaccharide derived from the deacetylation of chitin. The glucosamine units of chitosan

428   have a density of amine groups which permits strong electrostatic interactions with proteins

429   and genes. Additionally chitosan is mucoadhesive and has enhanced penetration capacity

430   across mucosal barriers.(10). Both of these nanoparticles are biodegradable, relatively non-

431   toxic and have been used as delivery systems for chlamydial vaccines. Two recent studies

432   using recombinant MOMP encapsulated in PLGA demonstrated enhanced capacity of the

433   peptide to induce Th1 cytokine, cellular and antibody immune response (33, 125). Cambridge

434   *et al*. demonstrated that MOMP was expressed in the muscle tissues and spleens of mice that

435   were intramuscularly injected with chitosan nanoparticles containing recombinant MOMP

436   DNA (14).

437 **Gas vesicles**

438 Gas vesicles are gas containing structures found in some bacteria and Archaea. These protein

439 structures are hollow, rigid, lipid-free, allow diffusion of gases across its membrane, and are

440 able to express peptides from various genes. Studies have shown that in the absence of

441 adjuvants, *Halobacteria* gas vesicles that displayed viral peptides elicited robust long-lived

442 immune response characterized by immunological memory in mice (120). *Halobacteria*-

443 derived gas vesicles that were loaded with gene fragments coding for MOMP, OmcB (outer

444 membrane complex B), and PompB (polymorphic outer membrane B) and expressed on the

445 surface were able to elicit a Th1 cytokine profile in human foreskin fibroblasts *in vitro*. In

446 addition the presence of the recombinant proteins were confirmed by anti-*Chlamydia*

447 antibodies and from *Chlamydia*-positive patient serum suggesting this could be an effective

448 antigen delivery system for a *Chlamydia* vaccine (20).

449

450 **ADJUVANTS**

451 Adjuvants enhance immunity and one of the main challenges in developing an

452 effective chlamydial vaccine is identifying antigen/adjuvant combinations that elicit a

453 protective immune response *in vivo*. Various adjuvant such as the ones mentioned in this

454 review (e.g. Freund`s adjuvant, ISCOM`s, CTB-CpG, CpG, bacterial ghosts) have been used

455 in chlamydial vaccine research with varying results. Recent research has added other new

456 antigen/adjuvant candidates with encouraging results. A study by Yu and colleagues

457 evaluated the chlamydial protein PmpG and five adjuvants, including three cationic liposome

458 formulations, Montanide ISA720-CpG-ODN1826 and alum. The results demonstrated that the

459 cationic liposomal adjuvants DDA-MPL and DDa-TDB elicited the best protective immune

460 responses against *C. muridarum*. Additionally, using DDA-MPL as an adjuvant along with 7

461 different T cell antigens (PmpG, PmpE, Aasf, Rp1F, TC0420, TC0825) conferred equal or

462 better protection than the vaccine antigen MOMP alone (142). This highlights the various

463 opportunities to further improve vaccine candidates by identifying the optimal

464 epitope/adjuvant combination

465

466 **VACCINATION ROUTES**

467 Vaccine efficacy is not only defined by the type of antigen and adjuvant used but also

468 by the administration route, since lymphocytes primed by antigens in vivo are endowed with

469 specialized homing programs guiding their migration to specific mucosal sites (95). Once

470 naive T cells are primed in a lymph node, a global switch of their homing program occurs

471 which enables them, while trafficking through the blood circulation, to detect chemokines and

472 adhesion molecules which direct them to their tissue destination. Lymphocytes, activated by

473 antigen presentation occurring in lymph nodes draining a mucosal site, acquire specialized

474 homing programs leading them to preferentially migrate to the same or other specific mucosal

475 sites. Of note, T cell homing to the genital mucosa involves either $\alpha1\beta1$, $\alpha4\beta1$ (110) or

476 $\alpha4\beta7$/E selectin (70) in *Chlamydia* infected mice. Both systemic and mucosal immunization

477 routes have been shown to be able to induce both humoral and cell-mediated immune

478 responses in the genital tract with intranasal immunization being often more effective (11,

479 94). Overall, mucosal immunization routes were more effective at preventing genital

480 challenges with a variety of pathogens (37, 44, 63, 77, 144).

481 Numerous immunization routes have been used for chlamydial vaccinations including

482 oral (48), intranasal (i.n.) (46), intravaginal (i.vag) (118), subcutaneous (107), intramuscular

483 (30), perivaginal (107), perisacral (107), sublingual v(113) and colonic (16). A study using

20

484   purified MOMP with a *Borrelia* surface protein as an adjuvant demonstrated that in two

485   different mouse strains "intramuscular + subcutaneous" and "perivaginal + perisacral"

486   immunization elicited high systemic (IgG) and mucosal (IgA) serum antibodies. In contrast,

487   the mice that received the MOMP-adjuvant i.n. had low IgG and IgA serum antibodies (107).

488   However, a recent study showed that i.n. immunization with rMOMP resulted in MOMP-

489   specific IgA and IgG antibodies in genital tract secretions demonstrating i.n. administration

490   may target immunity to the reproductive tract (23). Several studies comparing the protective

491   ability of various vaccination routes demonstrated that a combined mucosal and systemic

492   inoculation may be optimal. Using rMOMP with the adjuvants CpG and Montanide for

493   systemic route (intramuscular and subcutaneous) and rMOMP with cholera toxin for the

494   mucosal routes (sublingual and colonic), the authors demonstrated that following i.n. *C.*

495   *trachomatis* challenge the sublingual + intramuscular + subcutaneous group showed the best

496   protection (113). Another group demonstrated that mice immunized by combined mucosal

497   and systemic routes with *C. muridarum* recombinant MOMP plus the adjuvants CpG and

498   Montanide not only elicited the strongest chlamydia-specific humoral and cell-mediated

499   response after vaginal challenge with *C. muridarum* but also protected against infertility (16).

500

501   **CONCLUSIONS**

502   Chlamydial infection is a public health concern worldwide and a vaccine that

503   stimulates multiple arms of the adaptive immune system and avoids immunopathological

504   consequences would be the best solution for the control of this sexually transmitted disease.

505   Unfortunately, a partial or fully protective vaccine has yet to be developed highlighting the

506   complex nature of the immunobiology mounted against this intracellular parasitic bacterium.

507   The immune response to chlamydial infection is dynamic and involves cells and mediators

508   from both arms of the host's immune system. Clearance of a chlamydial infection requires a

509   coordinated immune response between innate immune cells such as macrophages, DC and

510   cells important in both cell-mediated and humoral adaptive responses such as CD4+T cells,

511   CD8+ T cells and B cells. Activation and clonal expansion of T cells occurs through cognate

512   interactions with DC that present chlamydial antigens on their MHC molecules and B cells

513   produce anti-chlamydial antibodies through interaction with these clonal T cells. However,

514   persistent infection seems to induce chronic inflammation and tissue damage. A shift from

515   Th1 to Th2 also appears to induce scarring and immune pathology. It is therefore essential to

516   understand these immunological dynamics in order to develop a vaccine that is both effective,

517   long-lasting and does not have the deleterious effects associated with unregulated

518   inflammation. Further research is needed to identify novel adjuvants that enhance the immune

519   response and antigens that induce a protective T cell response and anti-chlamydial antibodies.

520   A mathematical model developed by Gray and colleagues demonstrated that a fully

521   protective vaccine, administered to adolescents before they are sexually active, would be able

522   to eradicate *Chlamydia* infection in 20 years. In addition, the model predicted that vaccinating

523   100% of women would have a greater epidemiological impact than vaccinating both sexes

524   (42). Unfortunately there are risks and ethical questions associated with vaccination programs

525   as demonstrated by the first *Chlamydia* vaccine using live attenuated bacterium (43). Thus,

526   research is needed to develop an efficient and safe chlamydial vaccine.

527

528

REFERENCES

529

530   1.   **Agrawal, T., A. R. Bhengraj, V. Vats, S. Salhan, and A. Mittal.** 2011. Expression of TLR 2, TLR

531   4 and iNOS in cervical monocytes of Chlamydia trachomatis-infected women and their role in

532   host immune response. Am J Reprod Immunol **66:**534-43.

533   2.   **Al-Zeer, M. A., H. M. Al-Younes, D. Lauster, M. Abu Lubad, and T. F. Meyer.** 2013.

534   Autophagy restricts Chlamydia trachomatis growth in human macrophages via IFNG-

535   inducible guanylate binding proteins. Autophagy **9:**50-62.

536   3.   **Bachmaier, K., N. Neu, L. M. de la Maza, S. Pal, A. Hessel, and J. M. Penninger.** 1999.

537   Chlamydia infections and heart disease linked through antigenic mimicry. Science **283:**1335-

538   9.

539   4.   **Barenfanger, J., and A. B. MacDonald.** 1974. The role of immunoglobulin in the

540   neutralization of trachoma infectivity. J Immunol **113:**1607-17.

541   5.   **Bartolini, E., E. Ianni, E. Frigimelica, R. Petracca, G. Galli, F. B. Scorza, N. Norais, D. Laera, F.**

542   **Giusti, A. Pierleoni, M. Donati, R. Cevenini, O. Finco, G. Grandi, and R. Grifantini.** 2013.

543   Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce

544   antibodies that neurtralize chlamydial infection in vitro. Journal of Extracellular vesicles **2**.

545   6.   **Bas, S., L. Neff, M. Vuillet, U. Spenato, T. Seya, M. Matsumoto, and C. Gabay.** 2008. The

546   proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human

547   macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator,

548   through TLR2/TLR1/TLR6 and CD14. J Immunol **180:**1158-68.

549   7.   **Baud, D., L. Regan, and G. Greub.** 2008. Emerging role of Chlamydia and Chlamydia-like

550   organisms in adverse pregnancy outcomes. Curr Opin Infect Dis **21:**70-6.

551   8.   **Beagley, K. W., W. M. Huston, P. M. Hansbro, and P. Timms.** 2009. Chlamydial infection of

552   immune cells: altered function and implications for disease. Crit Rev Immunol **29:**275-305.

553   9.   **Bebear, C., and B. de Barbeyrac.** 2009. Genital Chlamydia trachomatis infections. Clin

554   Microbiol Infect **15:**4-10.

555   10.   **Boyoglu, S., K. Vig, S. Pillai, V. Rangari, V. A. Dennis, F. Khazi, and S. R. Singh.** 2009.

556   Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory

557   syncytial virus. Nanomedicine **5:**463-72.

558   11.   **Brandtzaeg, P.** 2009. Mucosal immunity: induction, dissemination, and effector functions.

559   Scand J Immunol **70:**505-15.

560   12.   **Brunham, R. C., and J. Rey-Ladino.** 2005. Immunology of Chlamydia infection: implications

561   for a Chlamydia trachomatis vaccine. Nat Rev Immunol **5:**149-61.

562   13.   **Byrne, G. I., R. S. Stephens, G. Ada, H. D. Caldwell, H. Su, R. P. Morrison, B. Van der Pol, P.**

563   **Bavoil, L. Bobo, S. Everson, and et al.** 1993. Workshop on in vitro neutralization of Chlamydia

564   trachomatis: summary of proceedings. J Infect Dis **168:**415-20.

565   14.   **Cambridge, C. D., S. R. Singh, A. B. Waffo, S. J. Fairley, and V. A. Dennis.** 2013. Formulation,

566   characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA

567   vaccine encapsulated in chitosan nanoparticles. Int J Nanomedicine **8:**1759-71.

568   15.   **Cao, H., R. G. Wolff, M. S. Meltzer, and R. M. Crawford.** 1989. Differential regulation of class

569   II MHC determinants on macrophages by IFN-gamma and IL-4. J Immunol **143:**3524-31.

570   16.   **Carmichael, J. R., S. Pal, D. Tifrea, and L. M. de la Maza.** 2011. Induction of protection

571   against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine

572   **29:**5276-83.

573   17.   **Chen, L., L. Lei, Z. Zhou, J. He, S. Xu, C. Lu, J. Chen, Z. Yang, G. Wu, I. T. Yeh, G. Zhong, and Y.**

574   **Wu.** 2013. Contribution of interleukin-12 p35 (IL-12p35) and IL-12p40 to protective immunity

575   and pathology in mice infected with Chlamydia muridarum. Infect Immun **81:**2962-71.

576   18.   **Cheng, C., I. Bettahi, M. I. Cruz-Fisher, S. Pal, P. Jain, Z. Jia, J. Holmgren, A. M. Harandi, and**

577   **L. M. de la Maza.** 2009. Induction of protective immunity by vaccination against Chlamydia

578   trachomatis using the major outer membrane protein adjuvanted with CpG

579   oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine **27:**6239-

580   46.

581   19.   **Cheng, C., S. Pal, I. Bettahi, K. L. Oxford, P. A. Barry, and L. M. de la Maza.** 2011.

582   Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native

583   major outer membrane protein in a nonhuman primate model. Vaccine **29:**3456-64.

584   20.   **Childs, T. S., and W. C. Webley.** 2012. In vitro assessment of halobacterial gas vesicles as a

585   Chlamydia vaccine display and delivery system. Vaccine **30:**5942-8.

586   21.   **Corsaro, D., and G. Greub.** 2006. Pathogenic potential of novel Chlamydiae and diagnostic

587   approaches to infections due to these obligate intracellular bacteria. Clin Microbiol Rev

588   **19:**283-97.

589   22.   **Crotzer, V. L., and J. S. Blum.** 2009. Autophagy and its role in MHC-mediated antigen

590   presentation. J Immunol **182:**3335-41.

591   23.   **Cunningham, K. A., A. J. Carey, L. Hafner, P. Timms, and K. W. Beagley.** 2011. Chlamydia

592   muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but

593   enhance pathology in vivo. Am J Reprod Immunol **65:**118-26.

594   24.   **de Clercq, E., I. Kalmar, and D. Vanrompay.** 2013. Animal models for studying Chlamydia

595   trachomatis female genital tract infection. Infect. Immun.

596   25.   **Deane, K. H., R. M. Jecock, J. H. Pearce, and J. S. Gaston.** 1997. Identification and

597   characterization of a DR4-restricted T cell epitope within chlamydia heat shock protein 60.

598   Clin Exp Immunol **109:**439-45.

599   26.   **Detmer, A., and J. Glenting.** 2006. Live bacterial vaccines--a review and identification of

600   potential hazards. Microb Cell Fact **5:**23.

601   27.   **Domeika, M., K. Domeika, J. Paavonen, P. A. Mardh, and S. S. Witkin.** 1998. Humoral

602   immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-

603   shock protein in women with pelvic inflammatory disease. J Infect Dis **177:**714-9.

604   28.   **Dong-Ji, Z., X. Yang, C. Shen, H. Lu, A. Murdin, and R. C. Brunham.** 2000. Priming with

605   Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP

606   ISCOM boosting enhances protection and is associated with increased immunoglobulin A and

607   Th1 cellular immune responses. Infect Immun **68:**3074-8.

608   29.   **Dong, F., M. Pirbhai, Y. Zhong, and G. Zhong.** 2004. Cleavage-dependent activation of a

609   chlamydia-secreted protease. Mol Microbiol **52:**1487-94.

610   30.   **Eko, F. O., E. Ekong, Q. He, C. M. Black, and J. U. Igietseme.** 2011. Induction of immune

611   memory by a multisubunit chlamydial vaccine. Vaccine **29:**1472-80.

612   31.   **Eko, F. O., D. N. Okenu, U. P. Singh, Q. He, C. Black, and J. U. Igietseme.** 2011. Evaluation of

613   a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine **29:**3802-10.

614   32.   **Entrican, G., N. Wheelhouse, S. R. Wattegedera, and D. Longbottom.** 2012. New challenges

615   for vaccination to prevent chlamydial abortion in sheep. Comp Immunol Microbiol Infect Dis

616   **35:**271-6.

617   33.   **Fairley, S. J., S. R. Singh, A. N. Yilma, A. B. Waffo, P. Subbarayan, S. Dixit, M. A. Taha, C. D.**

618   **Cambridge, and V. A. Dennis.** 2013. Chlamydia trachomatis recombinant MOMP

619   encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody

620   immune responses in mice: a desirable candidate nanovaccine. Int J Nanomedicine **8:**2085-

621   99.

622   34.   **Farris, C. M., S. G. Morrison, and R. P. Morrison.** 2010. CD4+ T cells and antibody are

623   required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia

624   muridarum genital infection. Infect Immun **78:**4374-83.

625 35. **Faurez, F., D. Dory, V. Le Moigne, R. Gravier, and A. Jestin.** 2010. Biosafety of DNA vaccines:

626 new generation of DNA vectors and current knowledge on the fate of plasmids after

627 injection. Vaccine **28**.

628 36. **Finco, O., E. Frigimelica, F. Buricchi, R. Petracca, G. Galli, E. Faenzi, E. Meoni, A. Bonci, M.**

629 **Agnusdei, F. Nardelli, E. Bartolini, M. Scarselli, E. Caproni, D. Laera, L. Zedda, D. Skibinski, S.**

630 **Giovinazzi, R. Bastone, E. Ianni, R. Cevenini, G. Grandi, and R. Grifantini.** 2011. Approach to

631 discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia

632 trachomatis vaccines. Proc Natl Acad Sci U S A **108:**9969-74.

633 37. **Gallichan, W. S., and K. L. Rosenthal.** 1998. Long-term immunity and protection against

634 herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic

635 immunization. J Infect Dis **177:**1155-61.

636 38. **Gaydos, C. A., C. Wright, B. J. Wood, G. Waterfield, S. Hobson, and T. C. Quinn.** 2008.

637 Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in

638 school-based health centers. Sex Transm Dis **35:**233-7.

639 39. **Gondek, D. C., A. J. Olive, G. Stary, and M. N. Starnbach.** 2012. CD4+ T cells are necessary

640 and sufficient to confer protection against Chlamydia trachomatis infection in the murine

641 upper genital tract. J Immunol **189:**2441-9.

642 40. **Goodall, J. C., H. Beacock-Sharp, K. H. Deane, and J. S. Gaston.** 2001. Recognition of the 60

643 kilodalton cysteine-rich outer membrane protein OMP2 by CD4(+) T cells from humans

644 infected with Chlamydia trachomatis. Clin Exp Immunol **126:**488-93.

645 41. **Goodall, J. C., G. Yeo, M. Huang, R. Raggiaschi, and J. S. Gaston.** 2001. Identification of

646 Chlamydia trachomatis antigens recognized by human CD4+ T lymphocytes by screening an

647 expression library. Eur J Immunol **31:**1513-22.

648   42.   **Gray, R. T., K. W. Beagley, P. Timms, and D. P. Wilson.** 2009. Modeling the impact of

649   potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J

650   Infect Dis **199:**1680-8.

651   43.   **Grayston, J. T., and S. P. Wang.** 1978. The potential for vaccine against infection of the

652   genital tract with Chlamydia trachomatis. Sex Transm Dis **5:**73-7.

653   44.   **Gupta, S., R. Janani, Q. Bin, P. Luciw, C. Greer, S. Perri, H. Legg, J. Donnelly, S. Barnett, D.**

654   **O'Hagan, J. M. Polo, and M. Vajdy.** 2005. Characterization of human immunodeficiency virus

655   Gag-specific gamma interferon-expressing cells following protective mucosal immunization

656   with alphavirus replicon particles. J Virol **79:**7135-45.

657   45.   **Hamdy, S., O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. Samuel, and A.**

658   **Lavasanifar.** 2008. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in

659   PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine

660   **26:**5046-57.

661   46.   **He, Q., L. Martinez-Sobrido, F. O. Eko, P. Palese, A. Garcia-Sastre, D. Lyn, D. Okenu, C.**

662   **Bandea, G. A. Ananaba, C. M. Black, and J. U. Igietseme.** 2007. Live-attenuated influenza

663   viruses as delivery vectors for Chlamydia vaccines. Immunology **122:**28-37.

664   47.   **He, Q., T. T. Moore, F. O. Eko, D. Lyn, G. A. Ananaba, A. Martin, S. Singh, L. James, J. Stiles,**

665   **C. M. Black, and J. U. Igietseme.** 2005. Molecular basis for the potency of IL-10-deficient

666   dendritic cells as a highly efficient APC system for activating Th1 response. J Immunol

667   **174:**4860-9.

668   48.   **Hickey, D. K., F. E. Aldwell, and K. W. Beagley.** 2010. Oral immunization with a novel lipid-

669   based adjuvant protects against genital Chlamydia infection. Vaccine **28:**1668-72.

670   49.   **Hjelholt, A., G. Christiansan, T. G. Johansson, H. J. Ingerslev, and S. Birkelund.** 2011. Tubal

671   factor infertility is associated with antibodies against Chlamydia trachomatis heat shock

672   protein 60 (HSP60) but not human HSP60. Human Reproduction **0**.

673 50. **Holland, M. J., D. J. Conway, T. J. Blanchard, O. M. Mahdi, R. L. Bailey, H. C. Whittle, and D.**

674 **C. Mabey.** 1997. Synthetic peptides based on Chlamydia trachomatis antigens identify

675 cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin Exp

676 Immunol **107:**44-9.

677 51. **Hosenfeld, C. B., K. A. Workowski, S. Berman, A. Zaidi, J. Dyson, D. Mosure, G. Bolan, and**

678 **H. M. Bauer.** 2009. Repeat infection with Chlamydia and gonorrhea among females: a

679 systematic review of the literature. Sex Transm Dis **36:**478-89.

680 52. **Huston, W. M., M. Harvie, A. Mittal, P. Timms, and K. W. Beagley.** 2012. Vaccination to

681 protect against infection of the female reproductive tract. Expert Rev Clin Immunol **8:**81-94.

682 53. **Ibana, J. A., L. Myers, C. Porretta, M. Lewis, S. N. Taylor, D. H. Martin, and A. J. Quayle.**

683 2012. The major CD8 T cell effector memory subset in the normal and Chlamydia

684 trachomatis-infected human endocervix is low in perforin. BMC Immunol **13:**66.

685 54. **Ibana, J. A., D. J. Schust, J. Sugimoto, T. Nagamatsu, S. J. Greene, and A. J. Quayle.** 2011.

686 Chlamydia trachomatis immune evasion via downregulation of MHC class I surface

687 expression involves direct and indirect mechanisms. Infect Dis Obstet Gynecol **2011:**420905.

688 55. **Ifere, G. O., Q. He, J. U. Igietseme, G. A. Ananaba, D. Lyn, W. Lubitz, K. L. Kellar, C. M. Black,**

689 **and F. O. Eko.** 2007. Immunogenicity and protection against genital Chlamydia infection and

690 its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect **40:**188-

691 200.

692 56. **Igietseme, J. U., and C. M. Black.** 2013. Chlamydial Infection: A Clinical and Public Health

693 Perspective, vol. 7.

694 57. **Igietseme, J. U., F. O. Eko, Q. He, and C. M. Black.** 2004. Antibody regulation of Tcell

695 immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev

696 Vaccines **3:**23-34.

697   58.   **Igietseme, J. U., and A. Murdin.** 2000. Induction of protective immunity against Chlamydia

698   trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic

699   immune response-stimulating complexes. Infect Immun **68:**6798-806.

700   59.   **Jawetz, E., L. Rose, L. Hanna, and P. Thygeson.** 1965. Experimental inclusion conjunctivitis in

701   man: measurements of infectivity and resistance. JAMA **194:**620-32.

702   60.   **Jayarapu, K., M. Kerr, S. Ofner, and R. M. Johnson.** 2010. Chlamydia-specific CD4 T cell

703   clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent

704   and -independent mechanisms. J Immunol **185:**6911-20.

705   61.   **Jendro, M. C., T. Deutsch, B. Korber, L. Kohler, J. G. Kuipers, B. Krausse-Opatz, J.**

706   **Westermann, E. Raum, and H. Zeidler.** 2000. Infection of human monocyte-derived

707   macrophages with Chlamydia trachomatis induces apoptosis of T cells: a potential

708   mechanism for persistent infection. Infect Immun **68:**6704-11.

709   62.   **Jendro, M. C., F. Fingerle, T. Deutsch, A. Liese, L. Kohler, J. G. Kuipers, E. Raum, M. Martin,**

710   **and H. Zeidler.** 2004. Chlamydia trachomatis-infected macrophages induce apoptosis of

711   activated T cells by secretion of tumor necrosis factor-alpha in vitro. Med Microbiol Immunol

712   **193:**45-52.

713   63.   **Jiang, J. Q., A. Patrick, R. B. Moss, and K. L. Rosenthal.** 2005. CD8+ T-cell-mediated cross-

714   clade protection in the genital tract following intranasal immunization with inactivated

715   human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol **79:**393-400.

716   64.   **Jiang, X., C. Shen, J. Rey-Ladino, H. Yu, and R. C. Brunham.** 2008. Characterization of murine

717   dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia

718   muridarum antigen presentation and induction of protective immunity. Infect Immun

719   **76:**2392-401.

720 65. **Johansson, M., and N. Lycke.** 2001. Immunological memory in B-cell-deficient mice conveys

721   long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid

722   recruitment of T cells. Immunology **102:**199-208.

723 66. **Johnson, R. M., H. Yu, M. S. Kerr, J. E. Slaven, K. P. Karunakaran, and R. C. Brunham.** 2012.

724   PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses

725   in Chlamydia muridarum-immune mice. Infect Immun **80:**2204-11.

726 67. **Kalbina, I., A. Wallin, I. Lindh, P. Engstrom, S. Andersson, and K. Strid.** 2011. A novel

727   chimeric MOMP antigen expressed in Escherichia coli, Arabidopsis thaliana, and Daucus

728   carota as a potential Chlamydia trachomatis vaccine candidate. Protein Expr Purif **80:**194-

729   202.

730 68. **Karaer, A., I. Mert, S. Cavkaytar, and S. Batioglu.** 2013. Serological investigation of the role

731   of selected sexually transmitted infections in the aetiology of ectopic pregnancy. Eur J

732   Contracept Reprod Health Care **18:**68-74.

733 69. **Kavanagh, K., L. A. Wallace, C. Robertson, P. Wilson, and A. Scoular.** 2013. Estimation of the

734   risk of tubal factor infertility associated with genital chlamydial infection in women: a

735   statistical modelling study. Int J Epidemiol **42:**493-503.

736 70. **Kelly, K. A., A. M. Chan, A. Butch, and T. Darville.** 2009. Two different homing pathways

737   involving integrin beta7 and E-selectin significantly influence trafficking of CD4 cells to the

738   genital tract following Chlamydia muridarum infection. Am J Reprod Immunol **61:**438-45.

739 71. **Kelly, K. A., J. C. Walker, S. H. Jameel, H. L. Gray, and R. G. Rank.** 2000. Differential

740   regulation of CD4 lymphocyte recruitment between the upper and lower regions of the

741   genital tract during Chlamydia trachomatis infection. Infect Immun **68:**1519-28.

742 72. **Kim, S. K., L. Devine, M. Angevine, R. DeMars, and P. B. Kavathas.** 2000. Direct detection

743   and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific

744   CD8+ CTLs with HLA class I tetramers. J Immunol **165:**7285-92.

745 73. **kumar, U., S. Kumar, S. Varghese, R. Chamoli, and P. Barthwal.** 2013. DNA Vaccine: A

746 modern biotechnological approach towards human welfare and clinical trials. International

747 Journal of Research in Biomedicine and Biotechnology **3:**17-20.

748 74. **Langemann, T., V. J. Koller, A. Muhammad, P. Kudela, U. B. Mayr, and W. Lubitz.** 2010. The

749 Bacterial Ghost platform system: production and applications. Bioeng Bugs **1:**326-36.

750 75. **Li, W., A. K. Murthy, B. K. Chaganty, M. N. Guentzel, J. Seshu, J. P. Chambers, G. Zhong, and**

751 **B. P. Arulanandam.** 2011. Immunization with dendritic cells pulsed ex vivo with recombinant

752 chlamydial protease-like activity factor induces protective immunity against genital

753 chlamydiamuridarum challenge. Front Immunol **2:**73.

754 76. **Li, Z., C. Lu, B. Peng, H. Zeng, Z. Zhou, Y. Wu, and G. Zhong.** 2012. Induction of protective

755 immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen

756 phosphorylase. PLoS One **7:**e32997.

757 77. **Lindqvist, M., J. Persson, K. Thorn, and A. M. Harandi.** 2009. The mucosal adjuvant effect of

758 alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral

759 infection. J Immunol **182:**6435-43.

760 78. **Longbottom, D.** 2003. Chlamydial vaccine development. J Med Microbiol **52:**537-40.

761 79. **Longbottom, D., and M. Livingstone.** 2006. Vaccination against chlamydial infections of man

762 and animals. Vet J **171:**263-75.

763 80. **Lu, C., B. Peng, Z. Li, L. Lei, Z. Li, L. Chen, Q. He, G. Zhong, and Y. Wu.** 2013. Induction of

764 protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial

765 immunodominant antigen macrophage infectivity potentiator. Microbes Infect **15:**329-38.

766 81. **Lu, H., H. Wang, H. M. Zhao, L. Zhao, Q. Chen, M. Qi, J. Liu, H. Yu, X. P. Yu, X. Yang, and W.**

767 **M. Zhao.** 2010. Dendritic cells (DCs) transfected with a recombinant adenovirus carrying

768 chlamydial major outer membrane protein antigen elicit protective immune responses

769 against genital tract challenge infection. Biochem Cell Biol **88:**757-65.

770 82. **Lu, H., and G. Zhong.** 1999. Interleukin-12 production is required for chlamydial antigen-

771   pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection.

772   Infect Immun **67:**1763-9.

773 83. **Luzardo-Alvarez, A., N. Blarer, K. Peter, J. F. Romero, C. Reymond, G. Corradin, and B.**

774   **Gander.** 2005. Biodegradable microspheres alone do not stimulate murine macrophages in

775   vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid

776   immune response in mice. J Control Release **109:**62-76.

777 84. **Matyszak, M. K., J. L. Young, and J. S. Gaston.** 2002. Uptake and processing of Chlamydia

778   trachomatis by human dendritic cells. Eur J Immunol **32:**742-51.

779 85. **Meeusen, E. N., J. Walker, A. Peters, P. P. Pastoret, and G. Jungersen.** 2007. Current status

780   of veterinary vaccines. Clin Microbiol Rev **20:**489-510, table of contents.

781 86. **Moore, T., G. A. Ananaba, J. Bolier, S. Bowers, T. Belay, F. O. Eko, and J. U. Igietseme.** 2002.

782   Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology

783   **105:**213-21.

784 87. **Morrison, R. P., K. Feilzer, and D. B. Tumas.** 1995. Gene knockout mice establish a primary

785   protective role for major histocompatibility complex class II-restricted responses in

786   Chlamydia trachomatis genital tract infection. Infect Immun **63:**4661-8.

787 88. **Morrison, S. G., and R. P. Morrison.** 2000. In situ analysis of the evolution of the primary

788   immune response in murine Chlamydia trachomatis genital tract infection. Infect Immun

789   **68:**2870-9.

790 89. **Morrison, S. G., and R. P. Morrison.** 2005. A predominant role for antibody in acquired

791   immunity to chlamydial genital tract reinfection. J Immunol **175:**7536-42.

792 90. **Murthy, A. K., B. K. Chaganty, W. Li, M. N. Guentzel, J. P. Chambers, J. Seshu, G. Zhong, and**

793   **B. P. Arulanandam.** 2009. A limited role for antibody in protective immunity induced by

794   rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge. FEMS

795   Immunol Med Microbiol **55:**271-9.

796   91.   **Murthy, A. K., J. P. Chambers, P. A. Meier, G. Zhong, and B. P. Arulanandam.** 2007.

797   Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital

798   Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent

799   upon endogenous gamma interferon production. Infect Immun **75:**666-76.

800   92.   **Murthy, A. K., W. Li, B. K. Chaganty, S. Kamalakaran, M. N. Guentzel, J. Seshu, T. G.**

801   **Forsthuber, G. Zhong, and B. P. Arulanandam.** 2011. Tumor necrosis factor alpha production

802   from CD8+ T cells mediates oviduct pathological sequelae following primary genital

803   Chlamydia muridarum infection. Infect Immun **79:**2928-35.

804   93.   **Murthy, A. K., W. Li, M. N. Guentzel, G. Zhong, and B. P. Arulanandam.** 2011. Vaccination

805   with the defined chlamydial secreted protein CPAF induces robust protection against female

806   infertility following repeated genital chlamydial challenge. Vaccine **29:**2519-22.

807   94.   **Naz, R. K.** 2012. Female genital tract immunity: distinct immunological challenges for vaccine

808   development. J Reprod Immunol **93:**1-8.

809   95.   **Nolz, J. C., G. R. Starbeck-Miller, and J. T. Harty.** 2011. Naive, effector and memory CD8 T-

810   cell trafficking: parallels and distinctions. Immunotherapy **3:**1223-33.

811   96.   **Nunes, A., P. J. Nogueira, M. J. Borrego, and J. P. Gomes.** 2010. Adaptive evolution of the

812   Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-

813   cell epitopes: worldwide survey. PLoS One **5**.

814   97.   **O'Connell, C. M., R. R. Ingalls, C. W. Andrews, Jr., A. M. Scurlock, and T. Darville.** 2007.

815   Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against

816   oviduct disease. J Immunol **179:**4027-34.

817   98.   **O'Meara, C. P., C. W. Armitage, M. C. Harvie, P. Timms, N. Y. Lycke, and K. W. Beagley.**

818   2013. Immunization with a MOMP-based vaccine protects mice against a pulmonary

819   Chlamydia challenge and identifies a disconnection between infection and pathology. PLoS

820   One **8:**e61962.

821   99.   **Ojcius, D. M., Y. Bravo de Alba, J. M. Kanellopoulos, R. A. Hawkins, K. A. Kelly, R. G. Rank,**

822   **and A. Dautry-Varsat.** 1998. Internalization of Chlamydia by dendritic cells and stimulation of

823   Chlamydia-specific T cells. J Immunol **160:**1297-303.

824   100.   **Olivares-Zavaleta, N., W. Whitmire, D. Gardner, and H. D. Caldwell.** 2010. Immunization

825   with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial

826   protection in a murine model of female genitourinary tract infection. Vaccine **28:**1454-62.

827   101.   **Olive, A. J., D. C. Gondek, and M. N. Starnbach.** 2011. CXCR3 and CCR5 are both required for

828   T cell-mediated protection against C. trachomatis infection in the murine genital mucosa.

829   Mucosal Immunol **4:**208-16.

830   102.   **Olsen, A. W., M. Theisen, D. Christensen, F. Follmann, and P. Andersen.** 2010. Protection

831   against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal

832   infection in a mouse genital challenge model. PLoS One **5:**e10768.

833   103.   **Organization, W. H.** 2008. Global incidence and prevalence of selected curable sexually

834   transmitted infections. World Health Organization, Geneva, Switzerland.

835   104.   **Ortiz, L., M. Angevine, S. K. Kim, D. Watkins, and R. DeMars.** 2000. T-cell epitopes in

836   variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-

837   specific immune responses in infected humans. Infect Immun **68:**1719-23.

838   105.   **Ou, C., D. Tian, Y. Ling, Q. Pan, Q. He, F. O. Eko, and C. He.** 2013. Evaluation of an ompA-

839   based phage-mediated DNA vaccine against Chlamydia abortus in piglets. Int

840   Immunopharmacol **16:**505-10.

841   106.   **Pal, S., K. M. Barnhart, Q. Wei, A. M. Abai, E. M. Peterson, and L. M. de la Maza.** 1999.

842   Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer

843   membrane protein elicits an immune response but fails to protect against a genital

844   challenge. Vaccine **17:**459-65.

845   107.   **Pal, S., C. J. Luke, A. G. Barbour, E. M. Peterson, and L. M. de la Maza.** 2003. Immunization

846   with the Chlamydia trachomatis major outer membrane protein, using the outer surface

847   protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial

848   genital challenge. Vaccine **21:**1455-65.

849   108.   **Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza.** 1997. Immunization with an

850   acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis

851   induces protection against a genital challenge. Infect Immun **65:**3361-9.

852   109.   **Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza.** 2001. Immunization with the

853   Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a

854   protective immune response against a genital challenge. Infect Immun **69:**6240-7.

855   110.   **Perry, L. L., K. Feilzer, J. L. Portis, and H. D. Caldwell.** 1998. Distinct homing pathways direct

856   T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice. J Immunol

857   **160:**2905-14.

858   111.   **Peschel, G., L. Kernschmidt, C. Cirl, N. Wantia, T. Ertl, S. Durr, H. Wagner, T. Miethke, and**

859   **N. Rodriguez.** 2010. Chlamydophila pneumoniae downregulates MHC-class II expression by

860   two cell type-specific mechanisms. Mol Microbiol **76:**648-61.

861   112.   **Picard, M. D., K. P. Cohane, T. M. Gierahn, D. E. Higgins, and J. B. Flechtner.** 2012. High-

862   throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable

863   of eliciting T cell and antibody responses that provide protection against vaginal challenge.

864   Vaccine **30:**4387-93.

865   113.   **Ralli-Jain, P., D. Tifrea, C. Cheng, S. Pal, and L. M. de la Maza.** 2010. Enhancement of the

866   protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic

867   and mucosal routes for immunization. Vaccine **28:**7659-66.

868   114.   **Rank, R. G., L. S. Soderberg, and A. L. Barron.** 1985. Chronic chlamydial genital infection in

869   congenitally athymic nude mice. Infect Immun **48:**847-9.

870   115.   **Refaat, B., M. Al-Azemi, I. Geary, A. Eley, and W. Ledger.** 2009. Role of activins and inducible

871   nitric oxide in the pathogenesis of ectopic pregnancy in patients with or without Chlamydia

872   trachomatis infection. Clin Vaccine Immunol **16:**1493-503.

873   116.   **Rey-Ladino, J., K. M. Koochesfahani, M. L. Zaharik, C. Shen, and R. C. Brunham.** 2005. A live

874   and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of

875   dendritic cells that are phenotypically and immunologically distinct. Infect Immun **73:**1568-

876   77.

877   117.   **Schautteet, K., E. De Clercq, Y. Jonsson, S. Lagae, K. Chiers, E. Cox, and D. Vanrompay.** 2012.

878   Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal

879   DNA immunization. Vaccine **30:**2869-81.

880   118.   **Schautteet, K., E. Stuyven, D. S. Beeckman, S. Van Acker, M. Carlon, K. Chiers, E. Cox, and D.**

881   **Vanrompay.** 2011. Protection of pigs against Chlamydia trachomatis challenge by

882   administration of a MOMP-based DNA vaccine in the vaginal mucosa. Vaccine **29:**1399-407.

883   119.   **Shaw, J., V. Grund, L. Durling, D. Crane, and H. D. Caldwell.** 2002. Dendritic cells pulsed with

884   a recombinant chlamydial major outer membrane protein antigen elicit a CD4(+) type 2

885   rather than type 1 immune response that is not protective. Infect Immun **70:**1097-105.

886   120.   **Sremac, M., and E. S. Stuart.** 2008. Recombinant gas vesicles from Halobacterium sp.

887   displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery

888   vehicle. BMC Biotechnol **8:**9.

889   121.   **Su, H., and H. D. Caldwell.** 1995. CD4+ T cells play a significant role in adoptive immunity to

890   Chlamydia trachomatis infection of the mouse genital tract. Infect Immun **63:**3302-8.

891   122.   **Su, H., R. Messer, W. Whitmire, E. Fischer, J. C. Portis, and H. D. Caldwell.** 1998. Vaccination

892   against chlamydial genital tract infection after immunization with dendritic cells pulsed ex

893   vivo with nonviable Chlamydiae. J Exp Med **188:**809-18.

894   123.   **Sun, G., S. Pal, J. Weiland, E. M. Peterson, and L. M. de la Maza.** 2009. Protection against an

895   intranasal challenge by vaccines formulated with native and recombinant preparations of the

896   Chlamydia trachomatis major outer membrane protein. Vaccine **27:**5020-5.

897   124.   **Sun, H. S., E. W. Eng, S. Jeganathan, A. T. Sin, P. C. Patel, E. Gracey, R. D. Inman, M. R.**

898   **Terebiznik, and R. E. Harrison.** 2012. Chlamydia trachomatis vacuole maturation in infected

899   macrophages. J Leukoc Biol **92:**815-27.

900   125.   **Taha, M. A., S. R. Singh, and V. A. Dennis.** 2012. Biodegradable PLGA85/15 nanoparticles as

901   a   delivery   vehicle   for   Chlamydia   trachomatis   recombinant   MOMP-187   peptide.

902   Nanotechnology **23:**325101.

903   126.   **Teng, A., M. I. Cruz-Fisher, C. Cheng, S. Pal, G. Sun, P. Ralli-Jain, D. M. Molina, P. L. Felgner,**

904   **X. Liang, and L. M. de la Maza.** 2012. Proteomic identification of immunodominant

905   chlamydial antigens in a mouse model. J Proteomics **77:**176-86.

906   127.   **Tifrea, D. F., P. Ralli-Jain, S. Pal, and L. M. de la Maza.** 2013. Vaccination with the

907   recombinant major outer membrane protein elicits antibodies to the constant domains and

908   induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.

909   Infect Immun **81:**1741-50.

910   128.   **Tifrea, D. F., G. Sun, S. Pal, G. Zardeneta, M. J. Cocco, J. L. Popot, and L. M. de la Maza.**

911   2011. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its

912   protective ability as a vaccine. Vaccine **29:**4623-31.

913   129.   **Van Voorhis, W. C., L. K. Barrett, Y. T. Sweeney, C. C. Kuo, and D. L. Patton.** 1996. Analysis of

914   lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper

915 genital tract of female macaques infected with Chlamydia trachomatis. J Infect Dis **174:**647-

916 50.

917 130. **Vasilevsky, S., J. Colino, R. Puliaev, D. H. Canaday, and C. M. Snapper.** 2008. Macrophages

918 pulsed with Streptococcus pneumoniae elicit a T cell-dependent antibody response upon

919 transfer into naive mice. J Immunol **181:**1787-97.

920 131. **Vergara, M. R. C., A. J. Buendia Marin, L. del Rio Alonzo, F. C. Gijon, N. O. Hernandez, M. C.**

921 **G. Ruiz, and J. S. Lorente.** 2005. Chlamydia trachomatis genital infection: Immunity and

922 prospects for vaccine development. Immunologia **24:**298-312.

923 132. **Vicetti Miguel, R. D., S. A. Harvey, W. A. LaFramboise, S. D. Reighard, D. B. Matthews, and**

924 **T. L. Cherpes.** 2013. Human female genital tract infection by the obligate intracellular

925 bacterium Chlamydia trachomatis elicits robust Type 2 immunity. PLoS One **8:**e58565.

926 133. **Waeckerle-Men, Y., B. Gander, and M. Groettrup.** 2005. Delivery of tumor antigens to

927 dendritic cells using biodegradable microspheres. Methods Mol Med **109:**35-46.

928 134. **Waeckerle-Men, Y., and M. Groettrup.** 2005. PLGA microspheres for improved antigen

929 delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev **57:**475-82.

930 135. **Wang, S. P., and J. T. Grayston.** 1991. Three new serovars of Chlamydia trachomatis: Da, Ia,

931 and L2a. J Infect Dis **163:**403-5.

932 136. **Witkin, S. S.** 2002. Immunological aspects of genital chlamydia infections. Best Pract Res Clin

933 Obstet Gynaecol **16:**865-74.

934 137. **Wizel, B., J. Nystrom-Asklin, C. Cortes, and A. Tvinnereim.** 2008. Role of CD8(+)T cells in the

935 host response to Chlamydia. Microbes Infect **10:**1420-30.

936 138. **Wyrick, P. B.** 2010. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis **201**

937 **Suppl 2:**S88-95.

938 139. **Xu, W., J. Liu, W. Gong, J. Chen, S. Zhu, and L. Zhang.** 2011. Protective immunity against

939 Chlamydia trachomatis genital infection induced by a vaccine based on the major outer

940 membrane multi-epitope human papillomavirus major capsid protein L1. Vaccine **29:**2672-8.

941 140. **Yasir, M., N. D. Pachikara, X. Bao, Z. Pan, and H. Fan.** 2011. Regulation of chlamydial

942 infection by host autophagy and vacuolar ATPase-bearing organelles. Infect Immun **79:**4019-

943 28.

944 141. **Yilma, A. N., S. R. Singh, S. J. Fairley, M. A. Taha, and V. A. Dennis.** 2012. The anti-

945 inflammatory cytokine, interleukin-10, inhibits inflammatory mediators in human epithelial

946 cells and mouse macrophages exposed to live and UV-inactivated Chlamydia trachomatis.

947 Mediators Inflamm **2012:**520174.

948 142. **Yu, H., K. P. Karunakaran, X. Jiang, C. Shen, P. Andersen, and R. C. Brunham.** 2012.

949 Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.

950 Infect Immun **80:**1510-8.

951 143. **Yu, H., K. P. Karunakaran, I. Kelly, C. Shen, X. Jiang, L. J. Foster, and R. C. Brunham.** 2011.

952 Immunization with live and dead Chlamydia muridarum induces different levels of protective

953 immunity in a murine genital tract model: correlation with MHC class II peptide presentation

954 and multifunctional Th1 cells. J Immunol **186:**3615-21.

955 144. **Zhang, X., A. A. Chentoufi, G. Dasgupta, A. B. Nesburn, M. Wu, X. Zhu, D. Carpenter, S. L.**

956 **Wechsler, S. You, and L. BenMohamed.** 2009. A genital tract peptide epitope vaccine

957 targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against

958 herpes simplex virus type 2 challenge. Mucosal Immunol **2:**129-43.

959 145. **Zhang, X. L., I. S. Tsui, C. M. Yip, A. W. Fung, D. K. Wong, X. Dai, Y. Yang, J. Hackett, and C.**

960 **Morris.** 2000. Salmonella enterica serovar typhi uses type IVB pili to enter human intestinal

961 epithelial cells. Infect Immun **68:**3067-73.

962   146.   **Zhong, G., P. Fan, H. Ji, F. Dong, and Y. Huang.** 2001. Identification of a chlamydial protease-

963   like activity factor responsible for the degradation of host transcription factors. J Exp Med

964   **193:**935-42.

965   147.   **Zhu, S., J. Chen, M. Zheng, W. Gong, X. Xue, W. Li, and L. Zhang.** 2010. Identification of

966   immunodominant linear B-cell epitopes within the major outer membrane protein of

967   Chlamydia trachomatis. Acta Biochim Biophys Sin (Shanghai) **42:**771-8.

968

969

Table 1. Summary of recent developments in chlamydial research including chlamydial strain/antigen utilized, cell type infected and immune response elicited

Cell type	Chlamydia/Antigen	Immune Response	Ref.
Mouse macrophage cell line (J774) and human macrophages	*C. trachomatis*	• Live and inactivated *Chlamydia* induced elevated IL-8, IL-1β, TNF-α, IL-6.	(3, 24)
Mouse (RAW) and human (THP-1) macrophage cell line	*C. trachomatis*	• Live *Chlamydia* induced autophagy.	(1, 22)
Human macrophages	*C. trachomatis*	• Live *Chlamydia* infected macrophages induced T cell apoptosis.	(10, 11)
Mouse BMDC	C. *muridarum*	• DC pulsed with UV-inactivated *Chlamydia* in vitro secreted elevated levels of IL-12. • DC pulsed with UV-inactivated *Chlamydia* and adoptively transferred into naive mice induced strong protection against live chlamydial lung infection. • IL-12$^{-/-}$ DC failed to induce Th-1 dominant response and did not induce strong protection against chlamydial infection.	(14)
Mouse BMDC	rMOMP	• DC pulsed with rMOMP secreted IL-12 and induced infection-sensitized CD4+T cells to secrete IFN-γ. • DC pulsed with rMOMP and adoptively transferred into naive mice generated a Th2 anti-MOMP immune response.	(21)
Mouse BMDC	*C. trachomatis*	• IL-10$^{-/-}$ DC pulsed with UV-inactivated *Chlamydia* caused early DC maturation, activation, increased ability to process and present antigens and enhanced the rate of Th1 activation.	(7)
Mouse BMDC	*C. muridarum*	• DC incubated with UV-inactivated *Chlamydia* expressed low levels of CD40 and CD80, secreted low levels of proinflammatory cytokines and exhibited reduced recognition by *Chlamydia*-specific CD4+ T cells. • Adoptive transfer of live EB-pulsed DC was more effective that UV Chlamydia at protecting mice against a live intranasal chlamydial challenge.	(20)
Mouse BMDC	*C. muridarum*	• DC pulsed with live EBs presented 45 MHC class II *C. muridarum* peptides mapping to 13 proteins. In contrast DC pulsed with heat or UV-inactivated *Chlamydia* presented only six MHC class II chlamydial peptides mapping to 3 proteins. • Only two epitopes were shared in common between live and inactivated *C. muridarum*.	(25)
Mouse BMDC	Recombinant adenovirus carrying *C. trachomatis* MOMP	• DC exhibited increased CD80 and MHC class II, IL-12 and were able to stimulate CD4+ T cell proliferation and IFN-γ. • Adoptively transferred MOMP transfected DC generated Th1-biased cytokine production, mucosal IgA and protected mice against chlamydial genital tract infection.	(13)
Mouse BMDC	UV *C. muridarum* + CpG or rCPAF + CpG	• DC pulsed with rCPAF + CpG exhibited increased CD86, CD80, CD40, MHC class II, IL-12 but not IL-10 and IL-4. • Mice adoptively immunized with rCPAF + CpG or UV *C. muridarum* + CpG pulsed DC produced elevated IFN-γ, IG1, IgG2a and exhibited reduced *Chlamydia* shedding and reduced oviduct pathology compared to infected mock-immunized mice.	(12)

Mouse T cells	*C. muridarum*	• Athymic nude mice established chronic genital tract infection whereas wild-type mice resolved infection in 20 days.	(19)
Mouse T cells	*C. trachomatis* T cell antigens + AbISCO-100	• Potent CD8+ T response, polyfunctional Th1-polarized CD4+ T cell responses (INF-γ, TNF-α, IL-2) and high protein specific Th1-skewed antibody response (IgG2c). • Adoptive transfer of CD4+ T cells and CD8+ T cells to naive non-immunized mice protected against *C. trachomatis* vaginal challenge whereas passive transfer of immune sera did not.	(18)
Mouse T cells	*C. muridarum* MOMP + CpG and Montanide ISA	• Vaccinated mice were depleted of CD4+ and CD8+ T cells and challenged vaginally with live *C. muridarum*. Depletion of CD4+ T cells, but not CD8+ T cells diminished vaccine-induced protection.	(4)
Mouse CD4+ T cells	*C. trachomatis*	• Genital tract *C. trachomatis* infection stimulated the activation and memory development of *C. trachomatis*-specific CD4+ T cells. • CD4+ T cells are necessary to confer protection against *C. trachomatis* infection.	(6)
Mouse CD4 + T cells	*C. muridarum*	• CD4 T cell clone-induced epithelial NO production was critical for controlling replication. • Most potent CD4+ T cell clones were dependent on T cell degranulation for chlamydial replication control.	(9)
Human CD4+ T cells	*C. trachomatis*	• CD4+ T cells from women with genital tract infection that were pulsed ex vivo with EB secreted significantly more IL-4 than TNF-α and INF-γ.	(23)
Mouse CD8+ T cells	*C. muridarum*	• TNF-α from CD8+ T cells contributed significantly to oviduct pathological sequelae, but not bacterial clearance, following genital chlamydial challenge.	(17)
Human CD8+ T cells	*C. trachomatis*	• Endocervix effector memory CD8+ T cells from *C. trachomatis* infected women expressed low perforin levels.	(8)
Human B cells/Antibodies		• Identified 21 antibody inducing antigens from *C. trachomatis*-infected patients sera.	(5)
Mouse B cells/Antibodies	Recombinant outer membrane vesicles carrying *C. muridarum* HtrA	• Mice immunized with outer membrane vesicles carrying HtrA induced anti-HtrA-specific antibodies that neutralized *C. muridarum* infectivity in vitro.	(2)
Mouse B cells/Antibodies	*C. muridarum* or MOMP monoclocal antibody (mAb)	• Passive immunization with serum from *C. muridarum* infected mice conferred a marked level of protection from *C. muridarum* genital reinfection and shortened the time of infection. • MOMP mAbs conferred significant level of immunity to reinfection and reduced shedding.	(15)
Mouse B cells/Antibodies	rCPAF + CpG	• Both wild-type and B cell deficient (μmT) mice vaccinated intranasally with rCPAF + CpG and challenged with live *C. muridarum* vaginally demonstrated comparable clearance and similar reductions in pathology.	(16)

1. **Al-Zeer, M. A., H. M. Al-Younes, D. Lauster, M. Abu Lubad, and T. F. Meyer.** 2013. Autophagy restricts Chlamydia trachomatis growth in human macrophages via IFNG-inducible guanylate binding proteins. Autophagy **9:**50-62.

2. **Bartolini, E., E. Ianni, E. Frigimelica, R. Petracca, G. Galli, F. B. Scorza, N. Norais, D. Laera, F. Giusti, A. Pierleoni, M. Donati, R. Cevenini, O. Finco, G. Grandi, and R. Grifantini.** 2013. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neurtralize chlamydial infection in vitro. Journal of Extracellular vesicles **2**.

3. **Bas, S., L. Neff, M. Vuillet, U. Spenato, T. Seya, M. Matsumoto, and C. Gabay.** 2008. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. J Immunol **180:**1158-68.

4. **Farris, C. M., S. G. Morrison, and R. P. Morrison.** 2010. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun **78:**4374-83.

5. **Finco, O., E. Frigimelica, F. Buricchi, R. Petracca, G. Galli, E. Faenzi, E. Meoni, A. Bonci, M. Agnusdei, F. Nardelli, E. Bartolini, M. Scarselli, E. Caproni, D. Laera, L. Zedda, D. Skibinski, S. Giovinazzi, R. Bastone, E. Ianni, R. Cevenini, G. Grandi, and R. Grifantini.** 2011. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A **108:**9969-74.

6. **Gondek, D. C., A. J. Olive, G. Stary, and M. N. Starnbach.** 2012. CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J Immunol **189:**2441-9.

7. **He, Q., T. T. Moore, F. O. Eko, D. Lyn, G. A. Ananaba, A. Martin, S. Singh, L. James, J. Stiles, C. M. Black, and J. U. Igietseme.** 2005. Molecular basis for the potency of IL-10-deficient dendritic cells as a highly efficient APC system for activating Th1 response. J Immunol **174:**4860-9.

8. **Ibana, J. A., L. Myers, C. Porretta, M. Lewis, S. N. Taylor, D. H. Martin, and A. J. Quayle.** 2012. The major CD8 T cell effector memory subset in the normal and Chlamydia trachomatis-infected human endocervix is low in perforin. BMC Immunol **13:**66.

9. **Jayarapu, K., M. Kerr, S. Ofner, and R. M. Johnson.** 2010. Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms. J Immunol **185:**6911-20.

10. **Jendro, M. C., T. Deutsch, B. Korber, L. Kohler, J. G. Kuipers, B. Krausse-Opatz, J. Westermann, E. Raum, and H. Zeidler.** 2000. Infection of human monocyte-derived macrophages with Chlamydia trachomatis induces apoptosis of T cells: a potential mechanism for persistent infection. Infect Immun **68:**6704-11.

11. **Jendro, M. C., F. Fingerle, T. Deutsch, A. Liese, L. Kohler, J. G. Kuipers, E. Raum, M. Martin, and H. Zeidler.** 2004. Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor-alpha in vitro. Med Microbiol Immunol **193:**45-52.

12. **Li, W., A. K. Murthy, B. K. Chaganty, M. N. Guentzel, J. Seshu, J. P. Chambers, G. Zhong, and B. P. Arulanandam.** 2011. Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challenge. Front Immunol **2:**73.

13. **Lu, H., H. Wang, H. M. Zhao, L. Zhao, Q. Chen, M. Qi, J. Liu, H. Yu, X. P. Yu, X. Yang, and W. M. Zhao.** 2010. Dendritic cells (DCs) transfected with a recombinant adenovirus carrying chlamydial major outer membrane protein antigen elicit protective immune responses against genital tract challenge infection. Biochem Cell Biol **88:**757-65.

14. **Lu, H., and G. Zhong.** 1999. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect Immun **67:**1763-9.

15. **Morrison, S. G., and R. P. Morrison.** 2005. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol **175:**7536-42.

16. **Murthy, A. K., B. K. Chaganty, W. Li, M. N. Guentzel, J. P. Chambers, J. Seshu, G. Zhong, and B. P. Arulanandam.** 2009. A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge. FEMS Immunol Med Microbiol **55:**271-9.

17. **Murthy, A. K., W. Li, B. K. Chaganty, S. Kamalakaran, M. N. Guentzel, J. Seshu, T. G. Forsthuber, G. Zhong, and B. P. Arulanandam.** 2011. Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection. Infect Immun **79:**2928-35.

18. **Picard, M. D., K. P. Cohane, T. M. Gierahn, D. E. Higgins, and J. B. Flechtner.** 2012. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine **30:**4387-93.

19. **Rank, R. G., L. S. Soderberg, and A. L. Barron.** 1985. Chronic chlamydial genital infection in congenitally athymic nude mice. Infect Immun **48:**847-9.

20. **Rey-Ladino, J., K. M. Koochesfahani, M. L. Zaharik, C. Shen, and R. C. Brunham.** 2005. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect Immun **73:**1568-77.

21. **Shaw, J., V. Grund, L. Durling, D. Crane, and H. D. Caldwell.** 2002. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4(+) type 2 rather than type 1 immune response that is not protective. Infect Immun **70:**1097-105.

22. **Sun, H. S., E. W. Eng, S. Jeganathan, A. T. Sin, P. C. Patel, E. Gracey, R. D. Inman, M. R. Terebiznik, and R. E. Harrison.** 2012. Chlamydia trachomatis vacuole maturation in infected macrophages. J Leukoc Biol **92:**815-27.

23. **Vicetti Miguel, R. D., S. A. Harvey, W. A. LaFramboise, S. D. Reighard, D. B. Matthews, and T. L. Cherpes.** 2013. Human female genital tract infection by the obligate intracellular bacterium Chlamydia trachomatis elicits robust Type 2 immunity. PLoS One **8:**e58565.

24. **Yilma, A. N., S. R. Singh, S. J. Fairley, M. A. Taha, and V. A. Dennis.** 2012. The anti-inflammatory cytokine, interleukin-10, inhibits inflammatory mediators in human epithelial cells and mouse macrophages exposed to live and UV-inactivated Chlamydia trachomatis. Mediators Inflamm **2012:**520174.

25. **Yu, H., K. P. Karunakaran, I. Kelly, C. Shen, X. Jiang, L. J. Foster, and R. C. Brunham.** 2011. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J Immunol **186:**3615-21.

Vaccines	**Advantages**	**Disadvantages**	**Ag/Adjuvants**	**Ag Immunization Route**	**Model/ _Chlamydia_ Infection Route**	**Immune Response**	**Ref.**
Intact _Chlamydia_	• Intact Ag • Native configuration • Replication • Humoral/Cellular immunity	• Requires refrigeration • Potential reverting to virulent strains • Large scale production difficult • Possible transmission to unvaccinated individuals	Plasmid-deficient _Chlamydia_ (CM972, CM3.1) Plasmid-Deficient _Chlamydia_ (L2)		Mouse / i.v. Mouse / i.v	• Elevated IgG2a (Th1); low levels of IgG1 (Th2) • Mutants do not stimulate TLR2-dependent cytokine production • Infected mice with mutant _Chlamydia_ and challenged with wt _Chlamydia_ are protected against oviduct disease • Elevated IgG2a; low IgG1; no IgA (mucosal) • No pathology in the urogenital tract induced by L2 • Mice vaccinated with plasmid-deficient bacterium were not protected from infection/inflammation with secondary wt chlamydial infection	(17) (19)
Purified Subunits	• Do not revert to virulent strains • Avoids undesirable antigens	• Expensive to produce • Purification not standardized • Difficult to maintain native conformation of antigen complex	MOMP + subunit B cholera toxin conjugated to CpG MOMP-ISCOM MOMP + Freund`s adjuvant MOMP + IC31 MOMP + CpG/Montanide	i.m. + s.c. i.n. or i.m. i.m + s.c i.m + s.c i.m + s.c	Mouse / i.n. Mouse / i.n. Mouse / i.v. Mouse / i.n. Rhesus macaque	• Elevated IgG2a, IgG3 (Th1); lower IgG1 • Elevated INF-γ (Th1) • i.m. induced highest INF-γ and IL-4 (Th2) • Vortexed MOMP elicited higher IgG2a vs IgG1 • Sonicated MOMP elicited higher IgG1 vs IgG2a • Higher IgG1 than IgG2a • Elevated IgG ,IgA, INF-γ and TNF-α	(2) (10) (23) (3) (4)
Recombinant Proteins	• High yields • Inexpensive	• Some proteins require post-translational modification • If produced in _E. coli_ possibility of endotoxin contamination	rMOMP + Cholera toxin/CpG or CTA1 rMOMP + CpG /Montonide rCPAF + IL-12 rCPAF + CpG rCTH1 + CAF01 rGlgP + CpG rMIP	s.l. or t.c. or i.n. i.m + s.c. i.n. i.n. s.c. i.m. i.m.	Mouse / i.n. Mouse / i.n. Mouse / i.v. Mouse / i.v. Mouse / i.v. Mouse / i.v. Mouse / i.v.	• Elevated IFN-γ and TNF-α • i.n. immunization with MOMP + either adjuvant protected mice from infection but not pathology • t.c. immunization with MOMP and CTA1-DD protected mice from pathology but _Chlamydia_ burden was same as control mice • Vaccination protected against fibrotic scarring in lungs • Elevated IgG2a and lower levels of IgG1 • Increased IFN-γ ; minimal IL-4 • Elevated IgG2a and IgA • Vaccination significantly prevented infertility • T cell production of TNF-α/IL-2/IFN-γ • anti-CTH1 IgG2a, IgG1 • Protection was solely CD4+T cell-mediated • Th1-dominant T cell response • Reduced hydrosalpinx severity • More IgG2a vs IgG1	(18) (27) (15) (16) (20) (12) (13)

			rCT043	i.m.	Mouse / i.n.	• Elevated IFN-γ and no IL-4 • Reduced hydrosalpinx severity • rCT043 reduces bacterial load in a mouse model of i.n. infection	(14)
			rCT823 + ISCOM and CT144 + ISCOM	s.c.	Mouse / i.v.	• Elevated INF-γ, TNF-α, IL-2 • No detectable IL-4 and IL-10 • Elevated IgG2c (Th1) but not IgG1	(24)
DNA Vaccines	• Cheap • Easy to produce • Can encode for multiple epitopes • Native conformation of antigenic determinants	• Safety • Possible genome integration • Anti-DNA antibodies • Not possible for non-proteins	DNA MOMP	i.m.	Mouse / i.v.	• Elevated levels of IgG2a and IgG1	(22)
			Priming with MOMP and secondary boost with DNA MOMP-ISCOM	i.m.	Mouse / i.n.	• Elevated levels of IgG2a, IgA and IFN-γ	(6)
			DNA MOMP + GM-CSF, enterotoxin (*E. coli*) A & B	i.n. + i.v.	Pig / i.v.	• Vaccination induced significant protection against genital challenge • Protection correlated with efficient T cell priming and elevated IgA • anti-MOMP antibodies and low IL-4 production	(25)
			ompA	i.m.	Pig / i.m.		(21)
Bacterial Ghosts	• Inactivation not required therefore relevant antigenic determinants are not denatured • Easy to produce • Require no refrigeration • Carriage of different antigens, DNA and drugs simultaneously • Recognition and phagocytosis by APC	• Presence of LPS	MOMP & PorB DNA plasmid	i.m.	Mouse / i.v.	• High levels of IgG2a and IgA	(9)
			PmpD & PorB DNA plasmid	i.m.	Mouse / i.v.	• High levels of IgG2a and IgA, IFN-γ and low levels of IL-5 (Th2)	(7)
Biodegradable Polymers	• Biodegradable • Non-toxic • High encapsulation capacity • PLGA`s are efficiently phagocytosed by DC and macrophages • Chitosan has mucosal adhesiveness properties and enhanced penetration across mucosal barrier		rMOMP encapsulated in PLGA	s.c	Mouse	• Elevated CD4+ and CD8+ T cells • Elevated INF-γ, IL-12; reduced IL-4, IL-10 • Elevated IgG2a; reduced IgG1	(8, 26)
			Chitosan containing rMOMP DNA	i.m.			(1)

Vaccines from Transgenic Plants	• Low cost production • Ease of use	• Requirement for strong adjuvant	MOMP introduced into *A. thaliana* and *D. carota*				(11)
Gas Vesicles	• Able to express peptides from various genes		Gen fragments coding for MOMP, OmcB, Pomp loaded into *Halobacteria*-derived gas vesicles			• Elicited Th-1 cytokines in human foreskin fibroblasts	(5)

* i.m. (intramuscular), s.c. (subcutaneous), i.n. (intranasal), s.l. (subligual), t.c. (trancutaneous), i.v. (intravaginal)

1. Cambridge, C. D., S. R. Singh, A. B. Waffo, S. J. Fairley, and V. A. Dennis. 2013. Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int J Nanomedicine 8:1759-71.

2. Cheng, C., I. Bettahi, M. I. Cruz-Fisher, S. Pal, P. Jain, Z. Jia, J. Holmgren, A. M. Harandi, and L. M. de la Maza. 2009. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine 27:6239-46.

3. Cheng, C., M. I. Cruz-Fisher, D. Tifrea, S. Pal, B. Wizel, and L. M. de la Maza. 2011. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31(R). Vaccine 29:2437-43.

4. Cheng, C., S. Pal, I. Bettahi, K. L. Oxford, P. A. Barry, and L. M. de la Maza. 2011. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine 29:3456-64.

5. Clifton, D. R., K. A. Fields, S. S. Grieshaber, C. A. Dooley, E. R. Fischer, D. J. Mead, R. A. Carabeo, and T. Hackstadt. 2004. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc Natl Acad Sci U S A 101:10166-71.

6. Dong-Ji, Z., X. Yang, C. Shen, H. Lu, A. Murdin, and R. C. Brunham. 2000. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect Immun 68:3074-8.

7. Eko, F. O., D. N. Okenu, U. P. Singh, Q. He, C. Black, and J. U. Igietseme. 2011. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine 29:3802-10.

8. Fairley, S. J., S. R. Singh, A. N. Yilma, A. B. Waffo, P. Subbarayan, S. Dixit, M. A. Taha, C. D. Cambridge, and V. A. Dennis. 2013. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomedicine 8:2085-99.

9. Ifere, G. O., Q. He, J. U. Igietseme, G. A. Ananaba, D. Lyn, W. Lubitz, K. L. Kellar, C. M. Black, and F. O. Eko. 2007. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect 40:188-200.

10. Igietseme, J. U., and A. Murdin. 2000. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun 68:6798-806.

11. Kalbina, I., A. Wallin, I. Lindh, P. Engstrom, S. Andersson, and K. Strid. 2011. A novel chimeric MOMP antigen expressed in Escherichia coli, Arabidopsis thaliana, and Daucus carota as a potential Chlamydia trachomatis vaccine candidate. Protein Expr Purif 80:194-202.

12. Li, Z., C. Lu, B. Peng, H. Zeng, Z. Zhou, Y. Wu, and G. Zhong. 2012. Induction of protective immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen phosphorylase. PLoS One 7:e32997.

13. Lu, C., B. Peng, Z. Li, L. Lei, Z. Li, L. Chen, Q. He, G. Zhong, and Y. Wu. 2013. Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator. Microbes Infect 15:329-38.

14. Meoni, E., E. Faenzi, E. Frigimelica, L. Zedda, D. Skibinski, S. Giovinazzi, A. Bonci, R. Petracca, E. Bartolini, G. Galli, M. Agnusdei, F. Nardelli, F. Buricchi, N. Norais, I. Ferlenghi, M. Donati, R. Cevenini, O. Finco, G. Grandi, and R. Grifantini. 2009. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun 77:4168-76.

15. Murthy, A. K., J. P. Chambers, P. A. Meier, G. Zhong, and B. P. Arulanandam. 2007. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun 75:666-76.

16. Murthy, A. K., W. Li, M. N. Guentzel, G. Zhong, and B. P. Arulanandam. 2011. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine 29:2519-22.

17. O'Connell, C. M., R. R. Ingalls, C. W. Andrews, Jr., A. M. Scurlock, and T. Darville. 2007. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol 179:4027-34.

18. O'Meara, C. P., C. W. Armitage, M. C. Harvie, P. Timms, N. Y. Lycke, and K. W. Beagley. 2013. Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology. PLoS One 8:e61962.

19. Olivares-Zavaleta, N., W. Whitmire, D. Gardner, and H. D. Caldwell. 2010. Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine 28:1454-62.

20. Olsen, A. W., M. Theisen, D. Christensen, F. Follmann, and P. Andersen. 2010. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 5:e10768.

21. Ou, C., D. Tian, Y. Ling, Q. Pan, Q. He, F. O. Eko, and C. He. 2013. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets. Int Immunopharmacol 16:505-10.

22. Pal, S., K. M. Barnhart, Q. Wei, A. M. Abai, E. M. Peterson, and L. M. de la Maza. 1999. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17:459-65.

23. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 2001. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 69:6240-7.

24. Picard, M. D., K. P. Cohane, T. M. Gierahn, D. E. Higgins, and J. B. Flechtner. 2012. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 30:4387-93.

25. Schautteet, K., E. De Clercq, Y. Jonsson, S. Lagae, K. Chiers, E. Cox, and D. Vanrompay. 2012. Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization. Vaccine 30:2869-81.

26. Taha, M. A., S. R. Singh, and V. A. Dennis. 2012. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology 23:325101.

27. Tifrea, D. F., P. Ralli-Jain, S. Pal, and L. M. de la Maza. 2013. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun 81:1741-50.